About Boof Reta

The problem

Lilly says it has reported more than 14,000 websites, ads, and social media posts selling illegal retatrutide in over 100 countries (Lilly, 2026). Pooled test data on research peptides shows large shares of vials failing basic quality checks (Mendias & Awan, 2026). Boof Reta exists so you can check a seller and its paperwork before you trust either one.

Editorial rules

• Every claim links to its source, and every number on the site appears in the source it cites.
• Sources come from regulators and peer-reviewed journals first, then from drugmakers, standards bodies, and consumer protection agencies. Preprints and pooled test data carry a “Not peer-reviewed” label.
• No vendor recommendations or rankings, and no affiliate links or discount codes. The site names no testing labs either.
• A company’s name appears only when the site cites a regulator’s or court’s document about it.
• No dosing or injection instructions.
• No invented quotes or numbers, and no made-up experts.

Independence

Boof Reta is an independent project that sells nothing and takes no money from anyone in the peptide trade. It has no ties to Eli Lilly or any seller. It isn’t a medical provider or a lab, and nothing on it is medical advice.

The “Last reviewed” date

On the date shown at the top of a page, someone re-checked every source and number on that page against the original. Pages get a review at least every 90 days, and sooner when a regulator or a study changes the facts.

Corrections log

• September 10, 2026: Site launched.

Sources for this page

1. Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market

   Eli Lilly and Company. Published August 12, 2026. Checked September 10, 2026. Archived copy.

   Lilly says no retatrutide medicine is approved anywhere; it filed six new lawsuits, referred 200+ parties to authorities, and reported 14,000+ sites, ads, posts and listings in 100+ countries.

2. Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance Not peer-reviewed

   Preprints.org (MDPI). Published April 24, 2026. Checked September 10, 2026. Archived copy.

   A preprint of 6,441 Finnrick-tested samples across 14 peptides finds 41.6% to 71.1% failed basic quality criteria, and 15% of 243 endotoxin-tested samples had measurable endotoxin.